Author: Carrie N. Baker

Carrie N. Baker, J.D., Ph.D., is the Sylvia Dlugasch Bauman professor of American Studies and the chair of the Program for the Study of Women and Gender at Smith College. She is a contributing editor at Ms. magazine. Read her latest book at Abortion Pills: U.S. History and Politics (Amherst College Press, December 2024). You can contact Dr. Baker at cbaker@msmagazine.com or follow her on Bluesky @carrienbaker.bsky.social.

Drugmaker GenBioPro Says Antiabortion Lawsuit Is ‘Extremist Attempt’ to Undermine FDA Authority

The pharmaceutical company GenBioPro filed a motion on Tuesday, Feb. 25, to intervene in Missouri et al. v. FDA, a lawsuit in Texas challenging FDA regulation of the drug mifepristone, which is part of a two-drug regimen for the termination of early pregnancy. GenBioPro is the sole U.S. manufacturer of generic mifepristone, which the FDA approved in 2019 and is now the majority of mifepristone sold in the U.S.

In the Texas lawsuit, the attorneys general of Missouri, Kansas and Idaho are attempting to remove generic mifepristone from the market and severely restrict the brand-name mifepristone, Mifeprex made by Danco, in all 50 states and U.S. territories.

“All people have a right to access safe, affordable, evidence-based healthcare, and GenBioPro remains committed to using all legal and regulatory tools to protect mifepristone for millions of patients and providers across the country,” said Evan Masingill, CEO of GenBioPro.

New York Times’ Shameful Reporting on Planned Parenthood Bolsters Right-Wing Attacks on Reproductive Healthcare Access

and

The New York Times recently published a 3,000-word investigative report claiming to have found “scores of allegations” against Planned Parenthood for misconduct, medical malpractice, mismanagement and labor violations. Released within a month of Trump’s inauguration, the article appears timed to provide ammunition for the ongoing right-wing attack on reproductive rights. 

The NYT could have invested its significant resources into investigating how Planned Parenthood plays a unique and irreplaceable role in the U.S. healthcare system as the nation’s leading provider of sexual and reproductive healthcare and largest sex educator. By choosing to publish what reads as a hit job on Planned Parenthood at this political moment, while failing to devote any resources to investigating the opaque and unregulated antiabortion industry vying to defund and replace Planned Parenthood, the NYT has done a grave disservice to readers, especially women and girls who need reproductive healthcare.

Rolling Up Our Sleeves, Part 3: Fighting the Trump Administration with State Constitutions

A fierce feminist resistance is ready to defend women’s rights at the federal level—and creatively expand equality protections in the states. This is the third in a four-part series on the steps activists are taking to fight for our rights amid Trump’s attacks on democracy.

(This is the third in a four-part series on the steps activists are taking to fight for our rights amid Trump administration’s attacks on democracy.)

Loretta Ross on ‘Calling In’: 25 Lessons on Change, Compassion and Cancel Culture

In Calling In: How to Start Making Change with Those You’d Rather Cancel, activist and scholar Loretta Ross challenges us to move beyond cancel culture and embrace a more humane approach to accountability. “A call in is a call out done with love,” she explains, emphasizing that true change requires “creating the conditions for differences of opinion to be heard” rather than relying on shame and ideological rigidity. With truth and history on our side, Ross urges us to build bridges, not burn them, leading a “revolution of moral renewal” that unites rather than divides.

‘Calling In’: Loretta Ross’ New Book Teaches How to ‘Model the World We Desire’

Reproductive justice founder Loretta Ross has a groundbreaking new book: Calling In: How to Start Making Change with Those You’d Rather Cancel. Ross draws on over 40 years of experience as a feminist activist to offer hope and guidance for how we can learn to communicate and work together across our differences of identity, political opinion and priorities. Calling In is part activist memoir, part how-to guide for calling in and part strategic plan for growing the human rights movement.

Beautifully written and engaging, Calling In is a guide to “compassionate politics”—an antidote to infighting and calling out that is weakening the women’s movement and the left today. 

Pa. Court to Hear Arguments *Feb. 5* on State Ban on Medicaid Coverage for Abortion and Equal Rights Amendment

In January 2024, the Pennsylvania Supreme Court ruled that abortion providers can challenge the Pennsylvania’s Medicaid coverage exclusion on abortion for violating the state’s Equal Rights Amendment and Non-Discrimination Clause of the Pennsylvania Constitution.

On Wednesday, Feb. 5, lawyers for Pennsylvania’s freestanding abortion clinics will argue before the Pennsylvania Commonwealth Court that the ban discriminates on the basis of sex in violation of these constitutional provisions.

The case is the first Pennsylvania state court proceeding challenging an abortion restriction since the state Supreme Court restored the Pennsylvania Equal Rights Amendment last year.

Research Supports New Medication Abortion Regime—But Some Fear Political Risks

Gynuity Health Projects has published new research in the New England Journal of Medicine suggesting that a double dose of ulipristal acetate (UPA), sold as an emergency contraceptive under the brand name Ella, taken in combination with the ulcer medication misoprostol, is an effective and acceptable medication abortion regimen with no reported serious adverse events. 

The current recognized clinical standard for first-trimester outpatient abortion is mifepristone and misoprostol, but mifepristone is tightly restricted by the FDA. Ulipristal acetate, on the other hand, currently has no such restrictions.

Some have expressed concern that this research could endanger access to Ella in the United States, and potentially also endanger the FDA-approved over-the-counter emergency contraception Plan B, made from the synthetic hormone levonorgestrel.

Rolling Up Our Sleeves, Part 2: Enlisting Blue State Government

A fierce feminist resistance is ready to defend women’s rights at the federal level—and creatively expand equality protections in the states. This is the second in a four-part series on the steps activists are taking to fight for our rights amid Trump’s attacks on democracy.

Part 1 covered the organization Democracy Forward and its new initiative Democracy 2025, which is working to counter the Trump administration’s antidemocratic acts with swift legal challenges and other strategic responses. This follow-up discusses the Democratic governors and attorney generals who are working to “Trump-proof” their state’s existing laws and fight for legal protections for their residents. Next Wednesday and Thursday, Part 3 will tackle more specifics of state law and advocacy, while Part 4 will get into the issue of federal funding under Trump.

Rolling Up Our Sleeves, Part 1: Fighting the New Trump Administration’s Wave of Extremist Actions

After a narrow political victory in November, a second Trump administration is now threatening to reverse decades of hard-fought gains for women and girls. Luckily, a fierce feminist resistance is ready to defend women’s rights at the federal level—and creatively expand equality protections in the states.

This is the first in a four-part series on the steps activists are taking to fight for our rights amid Trump’s attacks on democracy.